Core Insights - Amphastar Pharmaceuticals has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology for the development and commercialization of AMP-110, a synthetic human adrenocorticotropic hormone analog, in the U.S. and Canada [1] Company Summary - The agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions [1]